Australia markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.56-0.09 (-1.35%)
At close: 04:00PM EST
6.63 +0.07 (+1.07%)
After hours: 04:18PM EST
Full screen
Loading interactive chart…
  • Business Wire

    Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

    ATLANTA, January 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.

  • Business Wire

    Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

    ATLANTA, December 01, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that more than 50% of the patients planned for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1) study have been randomized.

  • Business Wire

    Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

    ATLANTA, November 11, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.